Skip to main content
OpenTrials
Completed

NCT Number: NCT05292092

Essential Pro PMCF Study ( rEPIC04E )

Multicenter, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of Essential Pro to meet EU Medical Device regulation (MDR) requirements in all the CONSECUTIVE patients treated with Essential Pro.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Coronary Artery Disease (CAD) Arterial Occlusive Diseases Arteriosclerosis Cardiovascular Diseases Coronary Artery Disease Coronary Disease Heart Diseases Ischemic Heart Disease Myocardial Ischemia Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospital Punta de Europa, Algeciras, Spain

Loading trial locations.

About this study

The objective of this multicenter, prospective, non-randomized, post-market clinical follow-up (PMCF) study is to confirm and support the clinical safety and performance of the Essential Pro in a NON-SELECTED, Real World population under daily clinical practice when used as intended by the manufacturer to meet EU Medical Device regulation requirements for post-market clinical follow-up.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient treated with Essential Pro according to routine hospital practice and following instructions for use
  • Informed consent signed

Exclusion criteria

  • Not meet inclusion criteria

Treatment and study plan

Essential pro

Drug

Patients in whom treatment with (Essential Pro) has been attempted

Primary outcomes

  1. Safety Endpoint. Freedom from Target Lesion Failure

    Time frame: 12 months

    Freedom from TARGET LESION FAILURE (TLF), composite endpoint of cardiac death, myocardial infarction (MI) and a new Target Lesion Revascularization (TLR).

Secondary outcomes

  1. Efficacy Endpoint. Freedom from Target Lesion Failure (TLF)

    Time frame: 12 months

    Freedom from TARGET LESION FAILURE (TLF), composite endpoint of Cardiac death, Myocardial infarction, and new Target Lesion Revascularization (TLR).

  2. Freedom from Balloon rupture

    Time frame: During percutaneous coronary intervention (PCI)

    Freedom from Balloon rupture

  3. Freedom from Hypotube rupture

    Time frame: During PCI

    Freedom from Hypotube rupture

  4. Freedom from Complicated withdrawal

    Time frame: During PCI

    Freedom from Complicated withdrawal

  5. Freedom from Coronary perforation

    Time frame: During PCI

    Freedom from Coronary perforation

  6. Freedom from Coronary dissection >C

    Time frame: During PCI

    Freedom from Coronary dissection >C

  7. Freedom from No reflow

    Time frame: During PCI

    Freedom from No reflow

  8. Freedom from Coronary thrombosis

    Time frame: During PCI

    Freedom from Coronary thrombosis

Sponsors and collaborators

Lead sponsor

Fundación EPIC

Other

Registry information

Official study title

Essential Pro Post-Market Clinical Follow-up Study

Acronym: rEPIC04E

Important dates

Study start
2022
Primary completion
2025
Study completion
2026
First posted
Mar 23, 2022
Registry last updated
Jan 21, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.